CC
MACK

Clearline Capital’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Clearline Capital’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-402,176
Closed -$1.22M – 67
2018
Q4 		$1.22M Sell
402,176
-5,631
-1% -$19.5K 0.84% 37
2018
Q3 		$1.71M Buy
407,807
+332,397
+441% +$1.4M 1.01% 31
2018
Q2 		$291K Buy
+75,410
New +$501K 0.19% 49

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Clearline Capital's MACK Position: Q1 2019 in Review

Clearline Capital sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2019, closing a stake of 402,176 shares — an estimated $1.22M sold.

Clearline Capital first reported a position in MACK in Q2 2018 and held it in 3 quarters. The position peaked at $1.71M in Q3 2018. 54 funds tracked by Wall St. Rank hold MACK as of Q1 2019.

  • Clearline Capital reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Clearline Capital sold 402,176 Merrimack Pharmaceuticals, Inc. shares in Q1 2019, an estimated $1.22M.
  • Clearline Capital first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2018 and held it in 3 quarters.
  • Clearline Capital's Merrimack Pharmaceuticals, Inc. position peaked at $1.71M in Q3 2018.
  • 54 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2019.

Based on Clearline Capital's 13F filing for Q1 2019, filed 15 May 2019.